Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02

Seth A. Rosenthal, Kyoungwha Bae, Kenneth Pienta, Mark L. Sobczak, Sucha O. Asbell, Raghu Rajan, Kevin J. Kerlin, Jeff M. Michalski, Howard M. Sandler

Research output: Contribution to journalArticle

Abstract

Purpose: Long-term androgen suppression plus radiotherapy (AS+RT) is standard treatment of high-risk prostate cancer. A randomized trial, Radiation Therapy Oncology Group trial 9902, was undertaken to determine whether adjuvant chemotherapy with paclitaxel, estramustine, and etoposide (TEE) plus AS+RT would improve disease outcomes with acceptable toxicity. Methods and Materials: High-risk (prostate-specific antigen 20-100 ng/mL and Gleason score ≥7; or Stage T2 or greater, Gleason score 8, prostate-specific antigen level

Original languageEnglish (US)
Pages (from-to)672-678
Number of pages7
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume73
Issue number3
DOIs
Publication statusPublished - Mar 1 2009
Externally publishedYes

    Fingerprint

Keywords

  • Chemotherapy
  • Prostate cancer
  • Randomized clinical trials
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this